Thorsten Frenzel1, Milena Tienken2, Merve Abel2, Christoph Berliner2, Susanne Klutmann2, Dirk Beyersdorff2,3, Rudolf Schwarz4, Andreas Krüll4, Peter Bannas2. 1. Ambulatory Center, Department for Radiation Oncology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. frenzel@uke.uni-hamburg.de. 2. Department for Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3. Martini Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 4. Ambulatory Center, Department for Radiation Oncology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Abstract
PURPOSE: To determine the impact of Gallium-68-labled prostate-specific membrane antigen positron-emission tomography/computed tomography ([68Ga]PSMA PET/CT) on radiotherapy planning for primary disease, biochemical cancer relapse, and advanced disease of prostate cancer. METHODS: A total of 106 patients with prostate cancer scheduled for radiation therapy underwent 120 [68Ga]PSMA PET/CT scans prior to radiotherapy treatment. In 20 cases, patients underwent [68Ga]PSMA PET/CT for primary therapy (PT), 75 cases were referred for biochemical relapse after surgery (RL), and 25 cases were intended for palliative treatment of localized metastases (MD). We retrospectively compared the impact of [68Ga]PSMA PET/CT on lesion detection and treatment decision to CT alone. RESULTS: [68Ga]PSMA PET/CT revealed a total of 271 positive lesions, whereas CT detected 86 lesions (32%). Overall, the radiotherapy regime was changed in 55 of 120 cases (46%) based on the higher detection rate of [68Ga]PSMA PET/CT: in 15% of cases with PT, in 43% of cases with RL, and in 44% of cases with MD. CONCLUSION: [68Ga]PSMA PET/CT is superior to CT alone for lesion detection in prostate cancer, thereby significantly impacting on radiotherapy planning for primary disease, biochemical cancer relapse, and advanced disease of prostate cancer.
PURPOSE: To determine the impact of Gallium-68-labled prostate-specific membrane antigen positron-emission tomography/computed tomography ([68Ga]PSMA PET/CT) on radiotherapy planning for primary disease, biochemical cancer relapse, and advanced disease of prostate cancer. METHODS: A total of 106 patients with prostate cancer scheduled for radiation therapy underwent 120 [68Ga]PSMA PET/CT scans prior to radiotherapy treatment. In 20 cases, patients underwent [68Ga]PSMA PET/CT for primary therapy (PT), 75 cases were referred for biochemical relapse after surgery (RL), and 25 cases were intended for palliative treatment of localized metastases (MD). We retrospectively compared the impact of [68Ga]PSMA PET/CT on lesion detection and treatment decision to CT alone. RESULTS: [68Ga]PSMA PET/CT revealed a total of 271 positive lesions, whereas CT detected 86 lesions (32%). Overall, the radiotherapy regime was changed in 55 of 120 cases (46%) based on the higher detection rate of [68Ga]PSMA PET/CT: in 15% of cases with PT, in 43% of cases with RL, and in 44% of cases with MD. CONCLUSION: [68Ga]PSMA PET/CT is superior to CT alone for lesion detection in prostate cancer, thereby significantly impacting on radiotherapy planning for primary disease, biochemical cancer relapse, and advanced disease of prostate cancer.
Authors: Anuradha Saokar; Tina Islam; Marion Jantsch; Mansi A Saksena; Peter F Hahn; Mukesh G Harisinghani Journal: Clin Imaging Date: 2010 Sep-Oct Impact factor: 1.605
Authors: S M Schwarzenböck; J Kurth; Ch Gocke; T Kuhnt; G Hildebrandt; B J Krause Journal: Eur J Nucl Med Mol Imaging Date: 2013-04-11 Impact factor: 9.236
Authors: Christina Bluemel; Fraenze Linke; Ken Herrmann; Iva Simunovic; Matthias Eiber; Christian Kestler; Andreas K Buck; Andreas Schirbel; Thorsten A Bley; Hans-Juergen Wester; Daniel Vergho; Axel Becker Journal: EJNMMI Res Date: 2016-10-26 Impact factor: 3.138
Authors: Florian Sterzing; Clemens Kratochwil; Hannah Fiedler; Sonja Katayama; Gregor Habl; Klaus Kopka; Ali Afshar-Oromieh; Jürgen Debus; Uwe Haberkorn; Frederik L Giesel Journal: Eur J Nucl Med Mol Imaging Date: 2015-09-25 Impact factor: 9.236
Authors: Nina-Sophie Schmidt-Hegemann; Chukwuka Eze; Minglun Li; Paul Rogowski; Christian Schaefer; Christian Stief; Alexander Buchner; Constantinos Zamboglou; Wolfgang Peter Fendler; Ute Ganswindt; Clemens Cyran; Peter Bartenstein; Claus Belka; Harun Ilhan Journal: J Nucl Med Date: 2018-12-14 Impact factor: 10.057
Authors: Shaojun Zhu; Nader Hirmas; Jeremie Calais; Matthias Eiber; Boris Hadaschik; Martin Stuschke; Ken Herrmann; Johannes Czernin; Amar U Kishan; Nicholas G Nickols; David Elashoff; Wolfgang P Fendler Journal: BMC Cancer Date: 2021-05-07 Impact factor: 4.430
Authors: Christoph Henkenberens; Ann-Kathrin Oehus; Thorsten Derlin; Frank Bengel; Tobias L Ross; Markus A Kuczyk; Stefan Janssen; Hans Christiansen; Christoph A J von Klot Journal: Strahlenther Onkol Date: 2020-05-12 Impact factor: 3.621
Authors: Marco M E Vogel; Sabrina Dewes; Eva K Sage; Michal Devecka; Jürgen E Gschwend; Matthias Eiber; Stephanie E Combs; Kilian Schiller Journal: Radiat Oncol Date: 2021-05-01 Impact factor: 4.309